Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Iggo

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Cell Reports|December 11, 2025
Cancer cells transfer invasive properties through microRNAs contained in collagen tracksLucile Rouyer, Léa Normand, Elodie Richard, et al.
British Journal of Cancer|July 15, 2015
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancerNathalie Quenel-Tueux, Marc Debled, Justine Rudewicz, et al.
The Lancet. Oncology|February 20, 2025
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trialHervé Bonnefoi, Florence Lerebours, Marina Pulido, et al.
Cancer Research|April 24, 2024
ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain FerroptosisRaj K Shrestha, Zeyad D Nassar, Adrienne R Hanson, et al.
Cell Death & Disease|June 2, 2026
USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancerDanielle Meiwen Fang, Raj K Shrestha, Beatriz German, et al.
Breast Cancer Research : BCR|July 2, 2025
Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinomaEsme Bullock, Aleksandra Rozyczko, Sana Shabbir, et al.
Cell Reports|January 6, 2021
Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate CancerRayzel C Fernandes, John Toubia, Scott Townley, et al.
Cell Reports|June 19, 2026
Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a membrane-bound TGF-β1-dependent mechanismThomas Boyer, Céline Blaye, Domitille Chalopin, et al.
Nature Medicine|January 19, 2021
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancerTheresa E Hickey, Luke A Selth, Kee Ming Chia, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Cell Reports|December 11, 2025
Cancer cells transfer invasive properties through microRNAs contained in collagen tracksLucile Rouyer, Léa Normand, Elodie Richard, et al.
British Journal of Cancer|July 15, 2015
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancerNathalie Quenel-Tueux, Marc Debled, Justine Rudewicz, et al.
The Lancet. Oncology|February 20, 2025
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trialHervé Bonnefoi, Florence Lerebours, Marina Pulido, et al.
Cancer Research|April 24, 2024
ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain FerroptosisRaj K Shrestha, Zeyad D Nassar, Adrienne R Hanson, et al.
Cell Death & Disease|June 2, 2026
USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancerDanielle Meiwen Fang, Raj K Shrestha, Beatriz German, et al.
Breast Cancer Research : BCR|July 2, 2025
Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinomaEsme Bullock, Aleksandra Rozyczko, Sana Shabbir, et al.
Cell Reports|January 6, 2021
Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate CancerRayzel C Fernandes, John Toubia, Scott Townley, et al.
Cell Reports|June 19, 2026
Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a membrane-bound TGF-β1-dependent mechanismThomas Boyer, Céline Blaye, Domitille Chalopin, et al.
Nature Medicine|January 19, 2021
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancerTheresa E Hickey, Luke A Selth, Kee Ming Chia, et al.
Pageof 5